Solid lipid nanoparticles as efficient drug and gene delivery systems: Recent breakthroughs

Advanced Pharmaceutical Bulletin

Volumn 5, Issue 2, 2015, Pages 151-159

  Dolatabadi, Jafar Ezzati Nazhad ^a,b   Valizadeh, Hadi ^b,c   Hamishehkar, Hamed ^c  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Colloidal carrier; Drug delivery; Gene delivery; Solid lipid nanoparticles

Indexed keywords

ACECLOFENAC; CAMPTOTHECIN; CARBOMER; DOCOSAHEXAENOIC ACID; DOXORUBICIN; INSULIN; ISONIAZID; LIPOPLEX; LOPINAVIR; METHOTREXATE; PACLITAXEL; PLASMID DNA; PYRAZINAMIDE; RIFAMPICIN; RISPERIDONE; SMALL INTERFERING RNA; SOLID LIPID NANOPARTICLE; TAMOXIFEN; TERBINAFINE;

ATOMIC FORCE MICROSCOPY; BIOCOMPATIBILITY; BLOOD BRAIN BARRIER; CHEMICAL MODIFICATION; CHEMICAL STRUCTURE; COMPLEX FORMATION; CYTOTOXICITY TEST; DRUG DELIVERY SYSTEM; EMULSION; EVAPORATION; GENE SILENCING; GENOTOXICITY ASSAY; HOMOGENIZATION; HYDROPHILICITY; INTRAPULMONARY DRUG ADMINISTRATION; LIPOPHILICITY; MICROEMULSION; MORPHOLOGY; NONVIRAL GENE DELIVERY SYSTEM; ORAL DRUG ADMINISTRATION; PARTICLE SIZE; REVIEW; SCANNING ELECTRON MICROSCOPY; SPRAY DRYING; STATIC ELECTRICITY; SUPERCRITICAL FLUID; SUSTAINED DRUG RELEASE; SYNTHESIS; TOPICAL DRUG ADMINISTRATION; TRANSMISSION ELECTRON MICROSCOPY; ULTRASONICATION; ZETA POTENTIAL;

EID: 84930406839     PISSN: 22285881     EISSN: 22517308     Source Type: Journal    
DOI: 10.15171/apb.2015.022     Document Type: Review

References (80)

1. Ezzati Nazhad Dolatabadi J, de la Guardia M. Nanomaterial-based electrochemical immunosensors as advanced diagnostic tools. Anal Methods 2014;6(12):3891-900. doi: 10.1039/c3ay41749b.
2. Jamali AA, Pourhassan-Moghaddam M, Dolatabadi JEN, Omidi Y. Nanomaterials on the road to microRNA detection with optical and electrochemical nanobiosensors. Trac-Trend Anal Chem 2014;55:24-42. doi: 10.1016/j.trac.2013.10.008.
3. Ezzati Nazhad Dolatabadi J, Hamishehkar H, Eskandani M, Valizadeh H. Formulation, characterization and cytotoxicity studies of alendronate sodium-loaded solid lipid nanoparticles. Colloids Surf B Biointerfaces 2014;117:21-8. doi: 10.1016/j.colsurfb.2014.01.055.
4. Rostami E, Kashanian S, Azandaryani AH, Faramarzi H, Dolatabadi JEN, Omidfar K. Drug targeting using solid lipid nanoparticles. Chem Phys Lipids 2014;181:56-61. doi: 10.1016/j.chemphyslip.2014.03.006.
5. Ezzati Nazhad Dolatabadi J, Hamishehkar H, Valizadeh H. Development of dry powder inhaler formulation loaded with alendronate solid lipid nanoparticles: Solid-state characterization and aerosol dispersion performance. Drug Dev Ind Pharm 2014:1-7. doi: 10.3109/03639045.2014.956111.
6. Ezzati Nazhad Dolatabadi J, Jamali AA, Hasanzadeh M, Omidi Y. Quercetin Delivery into Cancer Cells with Single Walled Carbon Nanotubes. Int J Biosci Biochem Bioinform 2011;1:21-5. doi: 10.7763/ijbbb.2011.v1.4.
7. Ezzati Nazhad Dolatabadi J, Omidi Y, Losic D. Carbon Nanotubes as an Advanced Drug and Gene Delivery Nanosystem. Curr Nanosci 2011;7(3):297-314. doi: 10.2174/157341311795542444.
8. Dolatabadi JEN, Mashinchian O, Ayoubi B, Jamali AA, Mobed A, Losic D, et al. Optical and electrochemical DNA nanobiosensors. TrAC, Trends Anal Chem 2011;30(3):459-72. doi: 10.1016/j.trac.2010.11.010.
9. Saei AA, Dolatabadi JEN, Najafi-Marandi P, Abhari A, de la Guardia M. Electrochemical biosensors for glucose based on metal nanoparticles. TrAC, Trends Anal Chem 2013;42:216-27. doi: 10.1016/j.trac.2012.09.011.
10. Pouton CW. Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and 'self-microemulsifying' drug delivery systems. Eur J Pharm Sci 2000;11 Suppl 2:S93-8. doi: 10.1016/s0928-0987(00)00167-6.
11. Muller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev 2002;54 Suppl 1:S131-55. doi: 10.1016/s0169-409x(02)00118-7.
12. Muller RH, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm 2000;50(1):161-77. doi: 10.1016/s0939-6411(00)00087-4.
13. Uner M, Yener G. Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives. Int J Nanomedicine 2007;2(3):289-300.
14. Manjunath K, Reddy JS, Venkateswarlu V. Solid lipid nanoparticles as drug delivery systems. Methods Find Exp Clin Pharmacol 2005;27(2):127-44.
15. Ahlin Grabnar PKJSm-KJ. Optimization of procedure parameters and physical stability of solid lipid nanoparticles in dispersions. Acta Pharmaceut 1998;48no:259-67.
16. Olbrich C, Gessner A, Kayser O, Muller RH. Lipid-drug-conjugate (LDC) nanoparticles as novel carrier system for the hydrophilic antitrypanosomal drug diminazenediaceturate. J Drug Target 2002;10(5):387-96. doi: 10.1080/1061186021000001832.
17. Kamble VA, Jagdale DM, Kadam VJ. Solid lipid nanoparticles as drug delivery system. Int J Pharm Biol Sci 2010;1:1-9.
18. Alda Jusceline L, Hulda Noemi Mamani C, Daniel B-A, Heloise Oliveira P, Carlos Raimundo Ferreira G. Production and characterization of lipid microparticles produced by spray cooling encapsulating a low molar mass hydrophilic compound. Food Sci Technol 2010;30(1):276-81. doi: 10.1590/s0101-20612010005000014.
19. Mukherjee S, Ray S, Thakur RS. Solid lipid nanoparticles: a modern formulation approach in drug delivery system. Indian J Pharm Sci 2009;71(4):349-58. doi: 10.4103/0250-474x.57282.
20. Kaiser CS, Rompp H, Schmidt PC. Pharmaceutical applications of supercritical carbon dioxide. Pharmazie 2001;56(12):907-26.
21. Gosselin PM, Thibert R, Preda M, Mcmullen JN. Polymorphic properties of micronized carbamazepine produced by RESS. Int J Pharm 2003;252(1-2):225-33. doi: 10.1016/s0378-5173(02)00649-x.
22. Sjostrom B, Bergenstahl B. Preparation of submicron drug particles in lecithin-stabilized o/w emulsions I. Model studies of the precipitation of cholesteryl acetate. Int J Pharm 1992;88(1-3):53-62. doi: 10.1016/0378-5173(92)90303-j.
23. Siekmann B, Westesen K. Investigations on solid lipid nanoparticles prepared by precipitation in O/W emulsions. Eur J Pharm Biopharm 1996;42:104-9.
24. Qi C, Chen Y, Jing QZ, Wang XG. Preparation and characterization of catalase-loaded solid lipid nanoparticles protecting enzyme against proteolysis. Int J Mol Sci 2011;12(7):4282-93. doi: 10.3390/ijms12074282.
25. Freitas C, Mullera RH. Spray-drying of solid lipid nanoparticles (SLN TM). Eur J Pharm Biopharm 1998;46(2):145-51. doi: 10.1016/s0939-6411(97)00172-0.
26. Pardeike J, Hommoss A, Muller RH. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int J Pharm 2009;366(1-2):170-84. doi: 10.1016/j.ijpharm.2008.10.003.
27. Yoon G, Park J, Yoon IS. Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs): recent advances in drug delivery. J Pharm Invest 2013;43(5):353-62. doi: 10.1007/s40005-013-0087-y.
28. Rizwan M, Aqil M, Talegaonkar S, Azeem A, Sultana Y, Ali A. Enhanced transdermal drug delivery techniques: an extensive review of patents. Recent Pat Drug Deliv Formul 2009;3(2):105-24. doi: 10.2174/187221109788452285.
29. Mehnert W, Mader K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev 2001;47(2-3):165-96. doi: 10.1016/s0169-409x(01)00105-3.
30. Taratula O, Kuzmov A, Shah M, Garbuzenko OB, Minko T. Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA. J Control Release 2013;171(3):349-57. doi: 10.1016/j.jconrel.2013.04.018.
31. Weyenberg W, Filev P, Van Den Plas D, Vandervoort J, De Smet K, Sollie P, et al. Cytotoxicity of submicron emulsions and solid lipid nanoparticles for dermal application. Int J Pharm 2007;337(1-2):291-8. doi: 10.1016/j.ijpharm.2006.12.045.
32. Perugini P, Tomasi C, Vettor M, Dazio V, Conti B, Genta I, et al. Influence of SLN matrix modification on"in vitro" and "in vivo" nanoparticle performances. Int J Pharm Pharm Sci 2010;2:37-42.
33. Fundaro A, Cavalli R, Bargoni A, Vighetto D, Zara GP, Gasco MR. Non-stealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin: pharmacokinetics and tissue distribution after i.v. administration to rats. Pharmacol Res 2000;42(4):337-43. doi: 10.1006/phrs.2000.0695.
34. Zara GP, Cavalli R, Bargoni A, Fundaro A, Vighetto D, Gasco MR. Intravenous administration to rabbits of non-stealth and stealth doxorubicin-loaded solid lipid nanoparticles at increasing concentrations of stealth agent: pharmacokinetics and distribution of doxorubicin in brain and other tissues. J Drug Target 2002;10(4):327-35. doi: 10.1080/10611860290031868.
35. Almeida AJ, Souto E. Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv Drug Deliv Rev 2007;59(6):478-90. doi: 10.1016/j.addr.2007.04.007.
36. Carrillo C, Sanchez-Hernandez N, Garcia-Montoya E, Perez-Lozano P, Sune-Negre JM, Tico JR, et al. DNA delivery via cationic solid lipid nanoparticles (SLNs). Eur J Pharm Sci 2013;49(2):157-65. doi: 10.1016/j.ejps.2013.02.011.
37. Wang Y, Wu W. In situ evading of phagocytic uptake of stealth solid lipid nanoparticles by mouse peritoneal macrophages. Drug Deliv 2006;13(3):189-92. doi: 10.1080/10717540500315930.
38. Ruckmani K, Sivakumar M, Ganeshkumar PA. Methotrexate loaded solid lipid nanoparticles (SLN) for effective treatment of carcinoma. J Nanosci Nanotechnol 2006;6(9-10):2991-5. doi: 10.1166/jnn.2006.457.
39. Yang SC, Lu LF, Cai Y, Zhu JB, Liang BW, Yang CZ. Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. J Control Release 1999;59(3):299-307. doi: 10.1016/s0168-3659(99)00007-3.
40. Chen DB, Yang TZ, Lu WL, Zhang Q. In vitro and in vivo study of two types of long-circulating solid lipid nanoparticles containing paclitaxel. Chem Pharm Bull (Tokyo) 2001;49(11):1444-7. doi: 10.1248/cpb.49.1444.
41. Bargoni A, Cavalli R, Zara GP, Fundaro A, Caputo O, Gasco MR. Transmucosal transport of tobramycin incorporated in solid lipid nanoparticles (SLN) after duodenal administration to rats. Part II-tissue distribution. Pharmacol Res 2001;43(5):497-502. doi: 10.1006/phrs.2001.0813.
42. Zara GP, Cavalli R, Fundaro A, Bargoni A, Caputo O, Gasco MR. Pharmacokinetics of doxorubicin incorporated in solid lipid nanospheres (SLN). Pharmacol Res 1999;40(3):281-6. doi: 10.1006/phrs.1999.0509.
43. Zara GP, Bargoni A, Cavalli R, Fundaro A, Vighetto D, Gasco MR. Pharmacokinetics and tissue distribution of idarubicin-loaded solid lipid nanoparticles after duodenal administration to rats. J Pharm Sci 2002;91(5):1324-33. doi: 10.1002/jps.10129.
44. Solaro R, Chiellini F, Battisti A. Targeted Delivery of Protein Drugs by Nanocarriers. Materials 2010;3(3):1928-80. doi: 10.3390/ma3031928.
45. Negi JS, Chattopadhyay P, Sharma AK, Ram V. Development of solid lipid nanoparticles (SLNs) of lopinavir using hot self nano-emulsification (SNE) technique. Eur J Pharm Sci 2013;48(1-2):231-9. doi: 10.1016/j.ejps.2012.10.022.
46. Silva AC, Kumar A, Wild W, Ferreira D, Santos D, Forbes B. Long-term stability, biocompatibility and oral delivery potential of risperidone-loaded solid lipid nanoparticles. Int J Pharm 2012;436(1-2):798-805. doi: 10.1016/j.ijpharm.2012.07.058.
47. Singh H, Bhandari R, Kaur IP. Encapsulation of Rifampicin in a solid lipid nanoparticulate system to limit its degradation and interaction with Isoniazid at acidic pH. Int J Pharm 2013;446(1-2):106-11. doi: 10.1016/j.ijpharm.2013.02.012.
48. Kamboj S, Bala S, Nair AB. Solid Lipid Nanoparticles: An effective lipid based technology for poorly water soluble drugs. Int J Pharm Sci Rev Res 2010;5(2):78-90.
49. Miao J, Du YZ, Yuan H, Zhang XG, Hu FQ. Drug resistance reversal activity of anticancer drug loaded solid lipid nanoparticles in multi-drug resistant cancer cells. Colloids Surf B Biointerfaces 2013;110:74-80. doi: 10.1016/j.colsurfb.2013.03.037.
50. Mussi SV, Silva RC, Oliveira MC, Lucci CM, Azevedo RB, Ferreira LA. New approach to improve encapsulation and antitumor activity of doxorubicin loaded in solid lipid nanoparticles. Eur J Pharm Sci 2013;48(1-2):282-90. doi: 10.1016/j.ejps.2012.10.025.
51. Goppert TM, Muller RH. Polysorbate-stabilized solid lipid nanoparticles as colloidal carriers for intravenous targeting of drugs to the brain: comparison of plasma protein adsorption patterns. J Drug Target 2005;13(3):179-87. doi: 10.1080/10611860500071292.
52. Cavalli R, Caputo O, Gasco MR. Preparation and characterization of solid lipid nanospheres containing paclitaxel. Eur J Pharm Sci 2000;10(4):305-9. doi: 10.1016/s0928-0987(00)00081-6.
53. Vaghasiya H, Kumar A, Sawant K. Development of solid lipid nanoparticles based controlled release system for topical delivery of terbinafine hydrochloride. Eur J Pharm Sci 2013;49(2):311-22. doi: 10.1016/j.ejps.2013.03.013.
54. Chawla V, Saraf SA. Rheological studies on solid lipid nanoparticle based carbopol gels of aceclofenac. Colloids Surf B Biointerfaces 2012;92:293-8. doi: 10.1016/j.colsurfb.2011.12.006.
55. Chen H, Chang X, Du D, Liu W, Liu J, Weng T, et al. Podophyllotoxin-loaded solid lipid nanoparticles for epidermal targeting. J Control Release 2006;110(2):296-306. doi: 10.1016/j.jconrel.2005.09.052.
56. Jenning V, Schafer-Korting M, Gohla S. Vitamin A-loaded solid lipid nanoparticles for topical use: drug release properties. J Control Release 2000;66(2-3):115-26. doi: 10.1016/s0168-3659(99)00223-0.
57. Santos Maia C, Mehnert W, Schaller M, Korting HC, Gysler A, Haberland A, et al. Drug targeting by solid lipid nanoparticles for dermal use. J Drug Target 2002;10(6):489-95. doi: 10.1080/1061186021000038364.
58. Weber S, Zimmer A, Pardeike J. Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC) for pulmonary application: a review of the state of the art. Eur J Pharm Biopharm 2014;86(1):7-22. doi: 10.1016/j.ejpb.2013.08.013.
59. Yang W, Peters JI, Williams RO 3rd. Inhaled nanoparticles-a current review. Int J Pharm 2008;356(1-2):239-47. doi: 10.1016/j.ijpharm.2008.02.011.
60. Gehr P, Bachofen M, Weibel ER. The normal human lung: ultrastructure and morphometric estimation of diffusion capacity. Respir Physiol 1978;32(2):121-40. doi: 10.1016/0034-5687(78)90104-4.
61. Cryan SA, Sivadas N, Garcia-Contreras L. In vivo animal models for drug delivery across the lung mucosal barrier. Adv Drug Deliv Rev 2007;59(11):1133-51. doi: 10.1016/j.addr.2007.08.023.
62. Liu J, Gong T, Fu H, Wang C, Wang X, Chen Q, et al. Solid lipid nanoparticles for pulmonary delivery of insulin. Int J Pharm 2008;356(1-2):333-44. doi: 10.1016/j.ijpharm.2008.01.008.
63. Videira M, Almeida AJ, Fabra A. Preclinical evaluation of a pulmonary delivered paclitaxel-loaded lipid nanocarrier antitumor effect. Nanomedicine 2012;8(7):1208-15. doi: 10.1016/j.nano.2011.12.007.
64. Zhang PR, Tu YF, Wang S, Wang YH, Xie Y, Li M, et al. Preparation and characterization of budesonide-loaded solid lipid nanoparticles for pulmonary delivery. J Chin Pharm Sci 2011;20(4):390-6. doi: 10.5246/jcps.2011.04.049.
65. Zeng XM, MacRitchie HB, Marriott C, Martin GP. Correlation between inertial impaction and laser diffraction sizing data for aerosolized carrier-based dry powder formulations. Pharm Res 2006;23(9):2200-9. doi: 10.1007/s11095-006-9055-9.
66. Jaafar-Maalej C, Andrieu V, Elaissari A, Fessi H. Beclomethasone-loaded lipidic nanocarriers for pulmonary drug delivery: preparation, characterization and in vitro drug release. J Nanosci Nanotechnol 2011;11(3):1841-51. doi: 10.1166/jnn.2011.3119.
67. Ezzati Nazhad Dolatabadi J, Hamishehkar H, De La Guardia M, Valizadeh H. A fast and simple spectrofluorometric method for the determination of alendronate sodium in pharmaceuticals. BioImpacts 2014;4(1):39-42. doi: 10.5681/bi.2014.005.
68. Kuo YC, Chung CY. Solid lipid nanoparticles comprising internal Compritol 888 ATO, tripalmitin and cacao butter for encapsulating and releasing stavudine, delavirdine and saquinavir. Colloids Surf B Biointerfaces 2011;88(2):682-90. doi: 10.1016/j.colsurfb.2011.07.060.
69. Wang Y, Zhu L, Dong Z, Xie S, Chen X, Lu M, et al. Preparation and stability study of norfloxacin-loaded solid lipid nanoparticle suspensions. Colloids Surf B Biointerfaces 2012;98:105-11. doi: 10.1016/j.colsurfb.2012.05.006.
70. Wonganan P, Lansakara PD, Zhu S, Holzer M, Sandoval MA, Warthaka M, et al. Just getting into cells is not enough: mechanisms underlying 4-(N)-stearoyl gemcitabine solid lipid nanoparticle's ability to overcome gemcitabine resistance caused by RRM1 overexpression. J Control Release 2013;169(1-2):17-27. doi: 10.1016/j.jconrel.2013.03.033.
71. Tran PA, Zhang L, Webster TJ. Carbon nanofibers and carbon nanotubes in regenerative medicine. Adv Drug Deliv Rev 2009;61(12):1097-114. doi: 10.1016/j.addr.2009.07.010.
72. Singh R, Pantarotto D, Mccarthy D, Chaloin O, Hoebeke J, Partidos CD, et al. Binding and condensation of plasmid DNA onto functionalized carbon nanotubes: toward the construction of nanotube-based gene delivery vectors. J Am Chem Soc 2005;127(12):4388-96. doi: 10.1021/ja0441561.
73. Ji SR, Liu C, Zhang B, Yang F, Xu J, Long J, et al. Carbon nanotubes in cancer diagnosis and therapy. Biochim Biophys Acta 2010;1806(1):29-35. doi: 10.1016/j.bbcan.2010.02.004.
74. Singh S. Nanomaterials as Non-viral siRNA Delivery Agents for Cancer Therapy. BioImpacts 2013;3(2):53-65.
75. Barar J, Omidi Y. Targeted Gene Therapy of Cancer: Second Amendment toward Holistic Therapy. BioImpacts 2013;3(2):49-51. doi: 10.5681/bi.2013.014.
76. Razi Soofiyani S, Baradaran B, Lotfipour F, Kazemi T, Mohammadnejad L. Gene therapy, early promises, subsequent problems, and recent breakthroughs. Adv Pharm Bull 2013;3(2):249-55. doi: 10.5681/apb.2013.041.
77. Elfinger M, Üzgün S, Rudolph C. Nanocarriers for gene delivery - polymer structure, targeting ligands and controlled-release devices. Curr Nanosci 2008;4(4):322-53. doi: 10.2174/157341308786306062.
78. Goncalves C, Berchel M, Gosselin MP, Malard V, Cheradame H, Jaffres PA, et al. Lipopolyplexes comprising imidazole/imidazolium lipophosphoramidate, histidinylated polyethyleneimine and siRNA as efficient formulation for siRNA transfection. Int J Pharm 2014;460(1-2):264-72. doi: 10.1016/j.ijpharm.2013.11.005.
79. Jin J, Bae KH, Yang H, Lee SJ, Kim H, Kim Y, et al. In vivo specific delivery of c-Met siRNA to glioblastoma using cationic solid lipid nanoparticles. Bioconjug Chem 2011;22(12):2568-72. doi: 10.1021/bc200406n.
80. Montana G, Bondi ML, Carrotta R, Picone P, Craparo EF, San Biagio PL, et al. Employment of cationic solid-lipid nanoparticles as RNA carriers. Bioconjug Chem 2007;18(2):302-8. doi: 10.1021/bc0601166.